Fig. 1

Expression profiles of endogenous ANXA1 in EVT-treated AIS patients and tMCAO/R-injured mice. a Plasma ANXA1 levels detected by ELISA in normal control subjects (n = 12) and AIS patients treated with EVT (n = 23). Data were presented as median and IQR, and were analyzed by Mann–Whitney U test. **p < 0.01, and ***p < 0.001. b Plasma ANXA1 levels or ∆ANXA1 levels in EVT-treated AIS patients with favorable (n = 11) and unfavorable (n = 12) clinical outcomes. ∆ANXA1: ANXA1 concentration on 2–3 days post-EVT minus pre-EVT ANXA1 concentration. Data were presented as median and IQR and were analyzed by Mann–Whitney U test. ns, not significant. **p < 0.01. c Spearman correlation coefficient analyses of correlation between plasma ANXA1 levels or ∆ANXA1 levels in AIS patients and 3-month mRS scores. d ELISA analyses of the expressions of ANXA1 in peripheral blood of tMCAO/R-injured mice. Data were presented as the mean ± SD (n = 12/group), and were analyzed by one-way ANOVA followed by Bonferroni’s multiple comparison test. *p < 0.05, **p < 0.01, and ***p < 0.001. e Representative western blotting bands and densitometric quantifications of ANXA1 in the peri-infarct cortex after tMCAO/R. Data were presented as the mean ± SD (n = 6/group) and were analyzed by one-way ANOVA followed by Bonferroni’s multiple comparison test. **p < 0.01, and ***p < 0.001